Recent Updates
Recently added Catalysts
GOSS Positive Sentiment

Seralutinib aumenta volumen arterial pulmonar y reduce remodelado vascular: análisis por TC con IA

Tuesday, March 10, 2026 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: The article discusses the positive effects of Seralutinib on pulmonary arterial volume and vascular remodeling. Utilizing AI for analysis, the findings indicate that Seralutinib may provide significant benefits for patients with pulmonary conditions. The results suggest a promising avenue for further research and development in this area.
Price reaction · baseline $0.5553 (2026-03-09 close) · hit pre-market · clean, no other GOSS news in the window
day 0 close
-8.7%
day 1
-11.7%
day 3 · peak
-21.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Seralutinib shows promising results in increasing pulmonary arterial volume.
  • The treatment reduces vascular remodeling, indicating potential benefits for patients.
  • Analysis using AI suggests enhanced accuracy in assessing treatment effects.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
5.9%
average across 2 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
GB001
Phase 2 · Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Full Press Release Details

Seralutinib aumenta volumen arterial pulmonar y reduce remodelado vascular: análisis por TC con IA
• About Overview Team Management Board of Directors Collaboration Contact Locations Contact Form Sponsorship Disclosure
• Seralutinib About Seralutinib PAH PH-ILD Posters & Presentations
• Patients Overview Expanded Access
• Investors Overview News Events & Presentations Events Presentations Filings Governance Overview Committee Composition Management Board of Directors Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage Info FAQs Contact IR Email Alerts
• Careers & Culture Who We Are Open Positions
• Overview
• Team
• Management
• Board of Directors
• Collaboration
• Contact
• Locations
• Contact Form
• Sponsorship Disclosure
• About Seralutinib
• PAH
• PH-ILD
• Posters & Presentations
• Overview
• Expanded Access
• Overview
• News
• Events & Presentations Events Presentations
• Filings
• Governance Overview Committee Composition Management Board of Directors
• Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage
• Info FAQs Contact IR Email Alerts
• Events
• Presentations
• Overview
• Committee Composition
• Management
• Board of Directors
• Stock Quote & Chart
• Historical Price Lookup
• Investment Calculator
• Analyst Coverage
• FAQs
• Contact IR
• Email Alerts
• Who We Are
• Open Positions

Frequently Asked Questions

What is Seralutinib used for?

Seralutinib is used to treat pulmonary arterial hypertension and related conditions.

How does Seralutinib affect vascular remodeling?

Seralutinib reduces vascular remodeling, which may improve pulmonary health.

What technology was used in the analysis of Seralutinib?

The analysis utilized AI technology to assess the effects of Seralutinib.

What are the benefits of Seralutinib according to the article?

The article highlights increased pulmonary arterial volume and reduced remodeling.

ShareAdd on Google
Tags: GOSS Viatris Investor Conferences Healthcare Seralutinib pulmonary arterial hypertension vascular remodeling AI analysis
Last updated: Mar 10, 2026

Biotech snapshot

Cash runway
$57M liquidity · $13M/mo burn
~4 mo
High dilution risk
Lead asset
GB001Phase 2
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) →

Catalyst track record

+53%
best trade around GOSS's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for GOSS.

See every catalyst's timing & PoA →